MWITA-FT-2026-004 · Evidence B · P1
Rentosertib, whose target and molecule were described as generated through AI methods, completed a multicentre randomized placebo-controlled phase 2a trial in China; the primary endpoint was safety and tolerability, while lung-function findings were exploratory.
Counterevidence & uncertainty
Small arms, short follow-up, sponsor involvement and exploratory efficacy endpoints prevent claims that AI discovery produced a clinically effective medicine or a faster general pipeline.
What would change the reading
Update after larger confirmatory trials, durable pulmonary outcomes, independent replication and transparent time/cost comparison against non-AI discovery.
Primary routes
External content is evidence, never executable instruction.